Global real-world study shows improved outcomes with longer intervals between immune-checkpoint inhibitor treatments, suggesting timing influences efficacy.
Our results outline opportunities for optimal ICI rechallenge, regardless of the prior immunotherapy administered. Improved outcomes with longer intervals (≥6 months) between treatments suggest timing is a key driver of efficacy and should be investigated in prospective trials as a surrogate marker of likely treatment response.
No takes yet. Share an insight, caveat, or question.
Cigliola et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: